Replimune Group, Inc.
REPL
$12.06
-$0.80-6.22%
NASDAQ
Corporate Info
Website
Phone Number
781 222 9600
Address
500 Unicorn Park Drive
Suite 303, 3rd Floor
Woburn, MA 01801
Suite 303, 3rd Floor
Woburn, MA 01801
Country
United States
Year Founded
2015
Details
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Employees
465
Business Description
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company’s proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.